Clinical medicine Oncology · 2008 · 35 citations · 36 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyDrug DeliveryCytotoxic ChemotherapyTargeted Cancer TherapyTargeted TherapyChemotherapy For Prostate CancerPeptide-linked ProdrugsSomatostatin Analog TherapySomatostatin AnaloguesSomatostatin PharmacologySomatostatin Receptor TargetingTumor-targeted Peptide ProdrugsTumor-targeting Peptides
The major problems of traditional chemotherapy are non-selectivity and non-specificity, resulting in severe toxic side effects. Peptides are a new-generation of drug-delivery vector to increase efficacy of this therapy and avoid the resulting damage. The cytotoxic somatostatin (SST) conjugate JF-10-81 was developed by coupling camptothecin (CPT) to the N-terminus of a SST analog (JF-07-69) using an activated carbamate linker. This conjugate selectively targets somatostatin receptor subtype 2 (SSTR2) and also retains high binding affinity and rapid internalization as well as anti-proliferative activity towards various tumor cells. JF-10-81 was tested for its inhibitory activity against the growth of human tumors which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) and prostate cancer (PC-3). Both SSTR2 mRNAs and proteins were detected in all these tumor cell lines. The conjugate displayed potent in vivo inhibitory activity, although some of the potency measured in in vitro experiments was lost. JF-10-81 was found to significantly inhibit growth of these SSTR-positive tumors, resulting in 87% tumor reduction in neuroblastoma IMR32 and 97% in leukemia MOLT-4 bearing animals, even inducing regression of CFPAC-1 tumors. SSTR-overexpressing BON tumors were unfortunately relatively CPT-insensitive in vitro, however, JF-10-81 again exhibited in vivo potency presumably by specifically increasing CPT concentrations inside the tumor cells so that the inhibition rate for JF-10-81 was 85%. Also, JF-10-81 was used to treat highly invasive PC-3 tumors where s.c. injections inhibited both tumor growth (almost 60% reduction) and tumor metastasis (over 70%). This conjugate demonstrated its broad and excellent anti-tumor activity by targeting SSTR2-specific tumor tissues, supporting that short peptides and their analogs may be applied as ideal drug-delivery carriers to improve the traditional chemotherapy.
36
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Shiladitya Sengupta, David A. Eavarone, Ishan Capila et al. · Nature · 2005 · 943 citations
Pharmacy, Oncology, Pharmaceutics +16
A Mouse Model of Human Breast Cancer Metastasis to Human Bone
Charlotte Kuperwasser, Scott Dessain, Benjamin E. Bierbaum et al. · Cancer Research · 2005 · 211 citations · Full text
Medicine, Cancer Biology, Oncology +14
Attila Nagy, Andrew V. Schally, Gábor Halmos et al. · Proceedings of the National Academy of Sciences · 1998 · 144 citations